AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20852438 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine tid (three times daily)
Number of subjects: 75
Study 20852438 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine bid and tid
Number of subjects: 75
Study 19839220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for chronic low back pain
Number of subjects: 0
Study 19839220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for osteoarthritis of the knee
Number of subjects: 0
Study 16938692 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruption condition (sentences interleaved)
Number of subjects: 0
Study 16938692 — intervention group
Group type: COMPARATOR
Intervention: Continuous condition (one passage before the other)
Number of subjects: 0
Study 16873967 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic manipulations designed to increase cerebral metabolic rate
Number of subjects: 0
Study 16873967 — intervention group
Group type: COMPARATOR
Intervention: Cerebral metabolic rate
Number of subjects: 0
Study 16873967 — intervention group
Group type: COMPARATOR
Intervention: Synaptic marker (synaptophysin)
Number of subjects: 0
Study 16873967 — intervention group
Group type: COMPARATOR
Intervention: Markers for cholinergic neurons
Number of subjects: 0
Study 12767648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control
Number of subjects: 200
Study 12767648 — intervention group
Group type: COMPARATOR
Intervention: Rate-control
Number of subjects: 200
Study 12767648 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 200
Study 10418209 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER (5-10 mg once daily, doubled if necessary)
Number of subjects: 70
Study 10418209 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem SR (90-180 mg once daily, doubled if necessary)
Number of subjects: 70
Study 10418209 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER and Diltiazem SR
Number of subjects: 70
Study 7592246 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus inhaler (salmeterol 50 micrograms twice daily)
Number of subjects: 0
Study 7592246 — intervention group
Group type: COMPARATOR
Intervention: Diskhaler inhaler (salmeterol 50 micrograms twice daily)
Number of subjects: 0
Study 7592246 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus inhaler
Number of subjects: 0
Study 7592246 — intervention group
Group type: COMPARATOR
Intervention: Diskhaler inhaler
Number of subjects: 0
Study 2087855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 0.3 mg
Number of subjects: 16
Study 2087855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 344087 — intervention group
Group type: EXPERIMENTAL
Intervention: Syn-Ergel
Number of subjects: 92
Study 344087 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 92
Study 30832580 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine
Number of subjects: 42
Study 30832580 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 42
Study 30832580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 28027338 — intervention group
Group type: EXPERIMENTAL
Intervention: ImPACT intervention
Number of subjects: 583
Study 28027338 — intervention group
Group type: COMPARATOR
Intervention: PACT control
Number of subjects: 583
Study 26053137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) for quantification of abdominal SC and PP adipose tissue
Number of subjects: 162
Study 26053137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 162
Study 23223103 — intervention group
Group type: EXPERIMENTAL
Intervention: Episure™ AutoDetect™ syringe
Number of subjects: 14
Study 23223103 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass syringe
Number of subjects: 14
Study 23223103 — intervention group
Group type: EXPERIMENTAL
Intervention: Episure™ AutoDetect™ syringe (when used first)
Number of subjects: 14
Study 21660300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg once daily
Number of subjects: 25
Study 21660300 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg twice daily
Number of subjects: 25
Study 21660300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 18977381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sine-wave masking
Number of subjects: 2
Study 18977381 — intervention group
Group type: EXPERIMENTAL
Intervention: Notched-noise masking
Number of subjects: 2
Study 16399266 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural frequencies presentation
Number of subjects: 0
Study 16399266 — intervention group
Group type: COMPARATOR
Intervention: Probabilities presentation
Number of subjects: 0
Study 16399266 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural frequencies presentation (sixth graders)
Number of subjects: 0
Study 16399266 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of children's responses
Number of subjects: 0
Study 15528910 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free gum containing 18.8 mg of CPP-ACP
Number of subjects: 0
Study 15528910 — intervention group
Group type: COMPARATOR
Intervention: Sugar-free gum not containing CPP-ACP (control)
Number of subjects: 0
Study 10976355 — intervention group
Group type: EXPERIMENTAL
Intervention: Returning gastric residual volumes
Number of subjects: 35
Study 10976355 — intervention group
Group type: COMPARATOR
Intervention: Discarding gastric residual volumes
Number of subjects: 35
Study 10976355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 9488234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg per day
Number of subjects: 16
Study 9488234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8162007 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (1 g/d for 2 weeks followed by 1.5 g/d)
Number of subjects: 61
Study 8162007 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (0.5 g/d for 1 month, 0.750 g/d during the second month, then 1 g/d)
Number of subjects: 61
Study 8162007 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A
Number of subjects: 61
Study 8162007 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B
Number of subjects: 61
Study 8162007 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 61
Study 3096633 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg ethinyl estradiol and 1.0 mg ethynodiol diacetate (EED)
Number of subjects: 136
Study 3096633 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg ethinyl estradiol and 1.0 mg norethindrone acetate (ENA)
Number of subjects: 136
Study 3096633 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg ethinyl estradiol and 0.5 mg d‐1 norgestrel (ENG)
Number of subjects: 136
Study 3096633 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-selected group of 50 women using alternative means of contraception)
Number of subjects: 136
Study 30422157 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor corneas with diabetes
Number of subjects: 1090
Study 30422157 — intervention group
Group type: COMPARATOR
Intervention: Donor corneas without diabetes
Number of subjects: 1090
Study 30422157 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient diagnosis of PACE
Number of subjects: 1090
Study 30422157 — intervention group
Group type: COMPARATOR
Intervention: Recipient diagnosis of Fuchs dystrophy
Number of subjects: 1090
Study 30422157 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative complications
Number of subjects: 1090
Study 30422157 — intervention group
Group type: COMPARATOR
Intervention: No operative complications
Number of subjects: 1090
Study 28521782 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support system (CDSS) for risky alcohol use intervention
Number of subjects: 221
Study 28521782 — intervention group
Group type: COMPARATOR
Intervention: Control CDSS (not specified)
Number of subjects: 221
Study 28521782 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT combined with CDSS intervention
Number of subjects: 221
Study 26134827 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation
Number of subjects: 2612
Study 26134827 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge
Number of subjects: 2612
Study 26134827 — intervention group
Group type: COMPARATOR
Intervention: Reported data
Number of subjects: 2612
Study 26134827 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 2612
Study 24241365 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dilution OL-HDF
Number of subjects: 8
Study 24241365 — intervention group
Group type: COMPARATOR
Intervention: Mixed OL-HDF
Number of subjects: 8
Study 21919543 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin/metformin ER 10mg/500mg FDC
Number of subjects: 40
Study 21919543 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10mg (Lipitor®) and metformin 500mg (Glucophage® XR)
Number of subjects: 40
Study 19883295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (OTU) 80 mg twice daily
Number of subjects: 86
Study 19883295 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg twice daily
Number of subjects: 86
Study 19883295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17016711 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg)
Number of subjects: 32
Study 17016711 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg)
Number of subjects: 32
Study 17016711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12764904 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM plus western medicine
Number of subjects: 79
Study 12764904 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 79
Study 11734672 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate therapy (400 mg/day for 6 weeks)
Number of subjects: 38
Study 11734672 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 38
Study 11734672 — intervention group
Group type: EXPERIMENTAL
Intervention: HTG patients
Number of subjects: 38
Study 9722865 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise protocol (elbow flexions at two workloads)
Number of subjects: 16
Study 9722865 — intervention group
Group type: EXPERIMENTAL
Intervention: Easier exercise protocol
Number of subjects: 16
Study 8060578 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 to 40 mg twice daily)
Number of subjects: 41
Study 8060578 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 to 50 mg twice daily)
Number of subjects: 41
Study 3051879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg daily)
Number of subjects: 34
Study 3051879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30455336 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin correction factor adjusted by 50%
Number of subjects: 17
Study 30455336 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin correction factor adjusted by 100%
Number of subjects: 17
Study 30455336 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin correction factor adjusted by 150%
Number of subjects: 17
Study 30455336 — intervention group
Group type: COMPARATOR
Intervention: Insulin correction factor adjusted by 0%
Number of subjects: 17
Study 30455336 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between 100% and 50% corrections
Number of subjects: 17
Study 30455336 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between 150% and 50% corrections
Number of subjects: 17
Study 28315809 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (15 weeks)
Number of subjects: 136
Study 28315809 — intervention group
Group type: COMPARATOR
Intervention: Education control (15 weeks)
Number of subjects: 136
Study 26581791 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity acute aerobic exercise
Number of subjects: 85
Study 26581791 — intervention group
Group type: COMPARATOR
Intervention: Video watching control group
Number of subjects: 85
Study 22901494 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 423
Study 22901494 — intervention group
Group type: COMPARATOR
Intervention: Telephone support
Number of subjects: 423
Study 22141598 — intervention group
Group type: EXPERIMENTAL
Intervention: 77 Gy in 35 fractions to the entire prostate plus an additional integrated microboost to the macroscopic tumor of 95 Gy in 35 fractions
Number of subjects: 566
Study 22141598 — intervention group
Group type: COMPARATOR
Intervention: 77 Gy in 35 fractions to the entire prostate
Number of subjects: 566
Study 22141598 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 566
Study 19911858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg once daily
Number of subjects: 0
Study 19911858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg once daily
Number of subjects: 0
Study 19911858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride (2 mg and 4 mg)
Number of subjects: 0
Study 19911858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 0
Study 17064648 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergoid SLIT for grass pollens (active treatment)
Number of subjects: 33
Study 17064648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 33
Study 15193479 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate, high‐dose recombinant human FSH, and a delayed, multidose GnRH antagonist
Number of subjects: 145
Study 15193479 — intervention group
Group type: COMPARATOR
Intervention: Standard long protocol
Number of subjects: 145
Study 10895837 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic glucose clamp technique (1.5 mU x kg(‐1) x min(‐1))
Number of subjects: 8
Study 10895837 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (5.01 +/‐ 0.02 mmol/l) maintained for 225 +/‐ 3 min
Number of subjects: 8
Study 10895837 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic condition (plasma glucose at 2.65 +/‐ 0.02 mmol/l for 90 min)
Number of subjects: 8
Study 10895837 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery phase after hypoglycemia
Number of subjects: 8
Study 8873690 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (0.005 to 0.10 mg/kg, single intravenous dose)
Number of subjects: 56
Study 2054714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) 200 IU per day
Number of subjects: 40
Study 2054714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) 100 IU per day
Number of subjects: 40
Study 2054714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) 50 IU per day
Number of subjects: 40
Study 2054714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6656850 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 41
Study 6656850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 30702412 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐contour lithium disilicate crown (LDS group)
Number of subjects: 105
Study 30702412 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite buildup and full‐contour lithium disilicate crown (P‐LDS group)
Number of subjects: 105
Study 30702412 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrown (EC group)
Number of subjects: 105
Study 30702412 — intervention group
Group type: COMPARATOR
Intervention: Endodontic access cavity only (Control group)
Number of subjects: 105
Study 30702412 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct microhybrid composite restoration with glass fiber post (CP group)
Number of subjects: 105
Study 30702412 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct microhybrid composite (C group)
Number of subjects: 105
Study 30702412 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber reinforced composite (GFRC group)
Number of subjects: 105
Study 28981891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 28981891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24450390 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography measurements including MMode and 2D measurements of left ventricular (LV) and left atrial (LA) dimensions, LV tissue Doppler imaging (TDI), and tricuspid annular plane systolic excursion (TAPSE)
Number of subjects: 455
Study 24450390 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography measurements
Number of subjects: 455
Study 24450390 — intervention group
Group type: COMPARATOR
Intervention: T2D treatment
Number of subjects: 455
Study 23834745 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs using report cards and receiving personal clarification (n=17)
Number of subjects: 26
Study 23834745 — intervention group
Group type: COMPARATOR
Intervention: Control group GPs (n=9)
Number of subjects: 26
Study 23834745 — intervention group
Group type: COMPARATOR
Intervention: GPs outside the study (n=200)
Number of subjects: 26
Study 21714897 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP/prealbumin ratio
Number of subjects: 155
Study 21714897 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP, albumin, prealbumin, cholesterol, CRP/albumin, CRP/cholesterol
Number of subjects: 155
Study 21714897 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls, maintenance hemodialysis, and peritoneal dialysis patients
Number of subjects: 155
Study 19446968 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (placebo patch)
Number of subjects: 68
Study 19446968 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 68
Study 19446968 — intervention group
Group type: COMPARATOR
Intervention: Denicotinized cigarettes
Number of subjects: 68
Study 17046476 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulized albuterol (15 mg) alone (A)
Number of subjects: 62
Study 17046476 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) (AI)
Number of subjects: 62
Study 17046476 — intervention group
Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 62
Study 17046476 — intervention group
Group type: COMPARATOR
Intervention: Control group (AI)
Number of subjects: 62
Study 14992872 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery (Group A)
Number of subjects: 400
Study 14992872 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery (Group B)
Number of subjects: 400
Study 11095346 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b at a dose of 5 million units (MU) daily
Number of subjects: 104
Study 11095346 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon at a dose of 3 MU three times a week (t.i.w.)
Number of subjects: 104
Study 11095346 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b at a dose of 5 MU daily
Number of subjects: 104
Study 8936541 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelled central venous catheters
Number of subjects: 16
Study 8936541 — intervention group
Group type: COMPARATOR
Intervention: Conventional central venous catheters
Number of subjects: 16
Study 1468213 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical contact lens
Number of subjects: 25
Study 1468213 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherical contact lens
Number of subjects: 25
Study 1468213 — intervention group
Group type: COMPARATOR
Intervention: Non-contact lens wearing eyes (Control)
Number of subjects: 25
Study 6148868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (once daily)
Number of subjects: 132
Study 6148868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol plus bendroflumethiazide (both once daily)
Number of subjects: 132
Study 6148868 — intervention group
Group type: COMPARATOR
Intervention: Nadolol alone
Number of subjects: 132
Study 6148868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (25 to 100 mg twice daily)
Number of subjects: 132
Study 3549364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary training (ST)
Number of subjects: 21
Study 3549364 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon training (MT)
Number of subjects: 21
Study 3549364 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control (C-NT)
Number of subjects: 21
Study 31970931 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (granuloma excision and AC wash)
Number of subjects: 39
Study 31970931 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (topical prednisolone and cycloplegic drops with orbital floor injection of Triamcinolone acetonide)
Number of subjects: 39
Study 31970931 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 39
Study 29145166 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a-tDCS)
Number of subjects: 10
Study 29145166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (c-tDCS)
Number of subjects: 10
Study 29145166 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 25899527 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal approach (n = 21)
Number of subjects: 41
Study 25899527 — intervention group
Group type: COMPARATOR
Intervention: Intravesical approach (n = 20)
Number of subjects: 41
Study 25899527 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal approach
Number of subjects: 41
Study 25037665 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) for TMD
Number of subjects: 44
Study 24225475 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based nursing pulmonary rehabilitation
Number of subjects: 0
Study 20522533 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (0.33 mg/kg per week)
Number of subjects: 16
Study 20522533 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment with GH
Number of subjects: 16